



January 4, 2018

Company name: RIBOMIC Inc.
Representative: Yoshikazu Nakamura, President and CEO
Stock code: 4591
Listing: Tokyo Stock Exchange, Mothers Market
Contact: Emiko Nakamura, Corporate Officer,
Corporate Planning Department

Organization of the Scientific Advisory Board for Clinical Trials of Anti-FGF2 Aptamer for Treating Age-Related Macular Degeneration

We are pleased to announce that Dr. Quan Dong Nguyen, Professor of Ophthalmology at the Byers Eye Institute at Stanford University, and Dr. Karl G. Csaky, the T. Boone Pickens Director of the Clinical Center of Innovation for Age-Related Macular Degeneration (AMD) and the Managing Director and Chief Medical Officer at the Retina Foundation of the Southwest have joined the scientific advisory board for RIBOMIC Inc.

Dr. Nguyen and Dr. Csaky are highly recognized ophthalmologists and clinician scientists specializing in retina and vitreous disorders. As scientific consultants, they will provide RIBOMIC with professional expertise for the design, coordination, and evaluation of clinical trials that RIBOMIC plans to start in 2018 for patients with AMD in the United States, evaluating the in-house developed anti-FGF2 aptamer (RBM-007).

RBM-007 exhibits a dual therapeutic potency to inhibit not only angiogenesis but also fibrosis (i.e., scar formation in the retina), which cannot be completely prevented by currently approved anti-VEGF drugs. Such dual potency will provide us with a novel therapeutic approach to AMD patients.

Yoshikazu Nakamura, President and CEO of RIBOMIC Inc., commented: *"We are very excited that Dr. Nguyen and Dr. Csaky join our RIBOMIC team as advisors to assist in the development of clinical trials to evaluate our novel compound RBM-007. I am very confident that their joining our endeavor following the medical expert agreement with Dr. Robert B. Bhisitkul, Professor of Ophthalmology at the University of California, San Francisco (UCSF) Medical Center, will help to establish the RIBOMIC team as a dream team of leading ophthalmologists from around the globe."*

On his appointment, Dr. Nguyen added: *"I am very pleased to collaborate with the leadership at RIBOMIC to develop a novel therapeutic agent that may aid patients with age-related macular degeneration (AMD) and other retinal vascular diseases. Our patients deserve our very best efforts in trying to preserve and improve their vision. I look forward to working with Dr. Nakamura, Dr. Bhisitkul, Dr. Csaky, and the RIBOMIC Team to conduct the most rigorous and most appropriate clinical trials to evaluate the potential role of RBM-007 as an anti-FGF2 aptamer."*

Profile of Quan Dong Nguyen, MD, MSc

Dr. Quan Dong Nguyen currently is Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine.



After completing his education in 2001, Dr. Nguyen joined the faculty at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, as Assistant Professor and then Associate Professor of Ophthalmology and Director of Medical Education. In 2013, he was appointed as the McGaw Endowed Chair in Ophthalmology, Professor and Chairman of the Department of Ophthalmology and the Inaugural Director of the Stanley M.

Truhlsen Eye Institute, and Assistant Dean for Translational Research at the University of Nebraska Medical Center.

Dr. Nguyen serves as principal investigator on multiple clinical trials sponsored by the National Eye Institute and other organizations for macular edema (from diabetes and uveitis), neovascular age-related macular degeneration (AMD), and ocular inflammatory and uveitic diseases, as well as co-investigator on numerous other clinical trials involving novel therapeutic agents. Dr. Nguyen is known for his innovative work in early proof-of-concept, first-in-human clinical trials to evaluate potential pharmacotherapeutic agents for retinal vascular and ocular inflammatory and uveitic diseases.

Dr. Nguyen received his baccalaureate from the Phillips Exeter Academy and his bachelor and master of science degrees simultaneously in Molecular Biophysics and Biochemistry from Yale University.

Subsequently, he earned his medical degree at the University of Pennsylvania School of Medicine. He completed an internship in Internal Medicine at the Massachusetts General Hospital and a residency in Ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. Dr. Nguyen also completed fellowships in Immunology and Uveitis at the Massachusetts Eye and Ear Infirmary, Ocular Immunology at the Wilmer Eye Institute of the Johns Hopkins Medical Institutions, and medical and surgical retina at the Schepens Eye Research Institute and the Massachusetts Eye and Ear Infirmary. Dr. Nguyen has authored over 250 peer-reviewed publications and book chapters

On his appointment, Dr. Csaky added: *“I am very excited to be part of a team evaluating a potentially clinically important molecule such as RBM-007”*

Profile of Karl G. Csaky, MD, PhD



Karl G. Csaky, M.D., Ph.D., is the T. Boone Pickens Director of the Clinical Center of Innovation for Age-Related Macular Degeneration, Managing Director and Chief Medical Officer of the Retina Foundation of the Southwest. His main area of interest is studying both clinical research and drug delivery development as it pertains to retina diseases. In particular Dr. Csaky is involved in multiple clinical trials in retina treatment, is studying vision function assessments of patients with various stage of AMD and developing drug delivery approaches for the treatment of retina diseases. In addition, Dr. Csaky has led several meetings with the FDA and NEI on evaluating

novel endpoints for retinal diseases. Dr. Csaky is a member of the Macula Society, Retina Society, and American Academy of Ophthalmology, ARVO and the American Society of Retinal Specialists. He finished a retina fellowship at the Wilmer Eye Institute, Johns Hopkins University and a post-doctoral fellowship at the National Cancer Institute. Dr. Csaky completed an internship in medicine at Duke University, his ophthalmology residency at Washington University, and was awarded a Fulbright Scholarship. He received his combined MD/PhD degree from the University of Louisville. Dr. Csaky has over 100 peer-reviewed publications and book chapters.

Profile of RIBOMIC

RIBOMIC is a bio-venture company centered on drug discovery. The company is engaged in the field of aptamer therapeutics, which is a type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company's core drug development platform, can be used for the development of many types of aptamer drugs. RIBOMIC is dedicated to the discovery of drugs that target the broad field of unmet medical needs, which encompasses pain, eye disorders, fibrosis and many other problems.